Analysts expect WST to report $2.08 EPS and $839.98M revenue for Q2 2026, up 13% and 9.6% year-over-year, respectively.
West Pharmaceutical Services (WST) will release its Q2 2026 earnings on July 23 before the market opens. The company is projected to post earnings per share of $2.08, reflecting a 13% increase from the same period last year.
Revenue is estimated at $839.98M, a 9.6% year-over-year rise. These figures align with consensus estimates compiled from analyst forecasts over the past two years. The results will provide insight into WST’s performance amid ongoing demand in its core markets.
No immediate market reaction details are available ahead of the release.